Enrico Liaci, Maurizio Negri, Francesco Maccarrone, Silvia Piccinini, Enrico Pasanisi, Andrea Bacciu, Filippo Di Lella
{"title":"小儿耳蜗内神经鞘瘤:病例系列及文献回顾。","authors":"Enrico Liaci, Maurizio Negri, Francesco Maccarrone, Silvia Piccinini, Enrico Pasanisi, Andrea Bacciu, Filippo Di Lella","doi":"10.5152/iao.2024.241645","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intracochlear schwannomas (ICSs) are a subtype of intralabyrinthine schwannomas, completely located in the cochlear lumen. ICSs are particularly rare in the pediatric population. Putative diagnosis is made on the basis of magnetic resonance findings with signal characteristics that should remain the same at follow-up imaging.</p><p><strong>Methods: </strong>A retrospective review was performed searching for pediatric patients affected by ICS treated at the Otolaryngology Department, Ospedale Ramazzini, Carpi (Italy), and Otolaryngology and Otoneurosurgery Department, Azienda Ospedaliero-Universitaria di Parma, (Italy). A scoping literature review of the period January 2000 - June 2024 was performed.</p><p><strong>Results: </strong>Two cases of ICS in pediatric patients are described. Neither family history nor genetic signs of neurofibromatosis type II were found. A single report was identified in the literature review. Data analysis resumes the pooled data of the latter case and the authors' patients. The most common symptom at presentation was progressive sensorineural hearing loss (66%). Mean pure tone average at diagnosis was 74.2 dB. Intracochlear location was in the basal turn in 2 cases and in the apical and middle turns in the third patient. All cases initially underwent a \"wait and scan\" strategy. The mean follow-up time was 23.3 months.</p><p><strong>Conclusion: </strong>Management planning of pediatric ICSs should be accurate as surgical removal may require partial or total cochlear demolition, resulting in vestibular dysfunction and precluding future positioning of a cochlear implant. Close clinical and radiological follow-up with serial MRI scans allows to evaluate both symptom progression and rate of growth, in order to provide patients with the best therapeutic option.</p>","PeriodicalId":94238,"journal":{"name":"The journal of international advanced otology","volume":"20 6","pages":"484-488"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11639579/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pediatric Intracochlear Schwannoma: Case Series and Review of the Literature.\",\"authors\":\"Enrico Liaci, Maurizio Negri, Francesco Maccarrone, Silvia Piccinini, Enrico Pasanisi, Andrea Bacciu, Filippo Di Lella\",\"doi\":\"10.5152/iao.2024.241645\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Intracochlear schwannomas (ICSs) are a subtype of intralabyrinthine schwannomas, completely located in the cochlear lumen. ICSs are particularly rare in the pediatric population. Putative diagnosis is made on the basis of magnetic resonance findings with signal characteristics that should remain the same at follow-up imaging.</p><p><strong>Methods: </strong>A retrospective review was performed searching for pediatric patients affected by ICS treated at the Otolaryngology Department, Ospedale Ramazzini, Carpi (Italy), and Otolaryngology and Otoneurosurgery Department, Azienda Ospedaliero-Universitaria di Parma, (Italy). A scoping literature review of the period January 2000 - June 2024 was performed.</p><p><strong>Results: </strong>Two cases of ICS in pediatric patients are described. Neither family history nor genetic signs of neurofibromatosis type II were found. A single report was identified in the literature review. Data analysis resumes the pooled data of the latter case and the authors' patients. The most common symptom at presentation was progressive sensorineural hearing loss (66%). Mean pure tone average at diagnosis was 74.2 dB. Intracochlear location was in the basal turn in 2 cases and in the apical and middle turns in the third patient. All cases initially underwent a \\\"wait and scan\\\" strategy. The mean follow-up time was 23.3 months.</p><p><strong>Conclusion: </strong>Management planning of pediatric ICSs should be accurate as surgical removal may require partial or total cochlear demolition, resulting in vestibular dysfunction and precluding future positioning of a cochlear implant. Close clinical and radiological follow-up with serial MRI scans allows to evaluate both symptom progression and rate of growth, in order to provide patients with the best therapeutic option.</p>\",\"PeriodicalId\":94238,\"journal\":{\"name\":\"The journal of international advanced otology\",\"volume\":\"20 6\",\"pages\":\"484-488\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11639579/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The journal of international advanced otology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5152/iao.2024.241645\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of international advanced otology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/iao.2024.241645","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:耳蜗内神经鞘瘤(ICSs)是一种完全位于耳蜗腔内的神经鞘瘤亚型。ICSs在儿科人群中尤为罕见。假定的诊断是根据磁共振发现的信号特征做出的,这些特征在后续成像中应该保持不变。方法:回顾性分析在意大利Carpi的Ospedale Ramazzini耳鼻喉科和意大利帕尔马的Azienda Ospedaliero-Universitaria di Parma耳鼻喉和耳神经外科接受治疗的小儿ICS患者。对2000年1月至2024年6月期间的范围文献进行了综述。结果:报告2例小儿ICS患者。没有发现II型神经纤维瘤病的家族史和遗传征象。在文献综述中发现了一份单独的报告。数据分析恢复后一病例和作者患者的汇总数据。最常见的症状是进行性感音神经性听力损失(66%)。诊断时平均纯音平均值为74.2 dB。2例耳蜗内定位于基底转,3例耳蜗内定位于根尖转和中转。所有病例最初都采用了“等待和扫描”策略。平均随访时间为23.3个月。结论:儿科ICSs的治疗计划应准确,因为手术切除可能需要部分或全部切除耳蜗,导致前庭功能障碍,并妨碍未来放置人工耳蜗。密切的临床和放射学随访与系列MRI扫描可以评估症状进展和生长速度,以便为患者提供最佳的治疗选择。
Pediatric Intracochlear Schwannoma: Case Series and Review of the Literature.
Background: Intracochlear schwannomas (ICSs) are a subtype of intralabyrinthine schwannomas, completely located in the cochlear lumen. ICSs are particularly rare in the pediatric population. Putative diagnosis is made on the basis of magnetic resonance findings with signal characteristics that should remain the same at follow-up imaging.
Methods: A retrospective review was performed searching for pediatric patients affected by ICS treated at the Otolaryngology Department, Ospedale Ramazzini, Carpi (Italy), and Otolaryngology and Otoneurosurgery Department, Azienda Ospedaliero-Universitaria di Parma, (Italy). A scoping literature review of the period January 2000 - June 2024 was performed.
Results: Two cases of ICS in pediatric patients are described. Neither family history nor genetic signs of neurofibromatosis type II were found. A single report was identified in the literature review. Data analysis resumes the pooled data of the latter case and the authors' patients. The most common symptom at presentation was progressive sensorineural hearing loss (66%). Mean pure tone average at diagnosis was 74.2 dB. Intracochlear location was in the basal turn in 2 cases and in the apical and middle turns in the third patient. All cases initially underwent a "wait and scan" strategy. The mean follow-up time was 23.3 months.
Conclusion: Management planning of pediatric ICSs should be accurate as surgical removal may require partial or total cochlear demolition, resulting in vestibular dysfunction and precluding future positioning of a cochlear implant. Close clinical and radiological follow-up with serial MRI scans allows to evaluate both symptom progression and rate of growth, in order to provide patients with the best therapeutic option.